“Move your money by early 2022,” Wall Street legend warns
A new form of technology will cause a massive shift in the wealth divide in 2022. Do you own the stocks that will be affected?
Details here…

NVC Insider Trading (Neovasc)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): C$306,063.66
Insider Selling (Last 12 Months): C$0.00

Neovasc Insider Trading History Chart

This chart shows the insider buying and selling history at Neovasc by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Neovasc Share Price & Price History

Current Price: C$0.00
Price Change: +0.30 (1.20%)
As of 03/10/2017 08:06 PM ET

This chart shows the closing price history over time for NVC up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
[FREE Report] 5 Growth Stocks Under $49
Stay focused on the long-term with these 5 growth stock picks.
Learn More.

Neovasc Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/19/2021Doug JanzenDirectorBuy100,000C$1.00C$99,712.80330,453
6/29/2021Doug JanzenDirectorBuy100,000C$1.24C$123,525.60230,453
6/21/2021Doug JanzenDirectorBuy48,398C$1.15C$55,580.2678,851
3/5/2021Paul GeyerDirectorBuy25,000C$1.09C$27,245.0098,333
6/12/2020Doug JanzenDirectorBuy100C$3.36C$336.00121,638
7/3/2019Paul GeyerDirectorSell5,357C$1.85C$9,910.45450
11/21/2018Paul GeyerDirectorSell5,343C$1.88C$10,025.50
See Full Table
Insider Selling at Neovasc?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Neovasc and related companies.

SEC Filings (Institutional Ownership Changes) for Neovasc (TSE:NVC)

Neovasc Inc. (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company's segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products. The Tiara is in preclinical/early clinical stage development to provide a minimally invasive transcatheter device for patients experiencing mitral regurgitation (MR) as a result of mitral heart valve disease. The Reducer is an hourglass-shaped, balloon-expandable, stainless steel, bare metal device, which is implanted in the coronary sinus, creating a restriction in venous outflow from the myocardium (the muscular layer of the heart wall). Neovasc produces Peripatch, a biological tissue product that is manufactured from pericardium.
Read More on Neovasc

Today's Range

Now: N/A

50 Day Range

MA: C$1.78
Low: C$1.78
High: C$1.78

52 Week Range

Now: N/A

Volume

46,869 shs

Average Volume

111,876 shs

Market Capitalization

C$140.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Neovasc?

Neovasc's top insider investors include:
  1. Doug Janzen (Director)
  2. Paul Geyer (Director)
Man who called 2020 Crash warns of huge event in 2022
A historic event in 2022 will cause a massive shift in the wealth divide. It could leave thousands of Americans under age 50 better off… while retirees will be left holding the scraps.
Details here…